Literature DB >> 31634862

2019 update of the drug resistance mutations in HIV-1.

Annemarie M Wensing1, Vincent Calvez2, Francesca Ceccherini-Silberstein3, Charlotte Charpentier4, Huldrych F Günthard5, Roger Paredes6, Robert W Shafer7, Douglas D Richman8.   

Abstract

The 2019 edition of the IAS-USA drug resistance mutations list updates the Figure last published in January 2017. The mutations listed are those that have been identified by specific criteria for evidence and drugs described. The Figure is designed to assist practitioners in identifying key mutations associated with resistance to antiretroviral drugs, and therefore, in making clinical decisions regarding antiretroviral therapy.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31634862      PMCID： PMC6892618     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN： 2161-5853


  108 in total

1.  Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

Authors:  Jean-Michel Molina; Kathleen Squires; Paul E Sax; Pedro Cahn; Johan Lombaard; Edwin DeJesus; Ming-Tain Lai; Xia Xu; Anthony Rodgers; Lisa Lupinacci; Sushma Kumar; Peter Sklar; Bach-Yen Nguyen; George J Hanna; Carey Hwang
Journal:  Lancet HIV       Date:  2018-03-25       Impact factor: 12.767

2.  Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.

Authors:  Zixin Hu; Daniel R Kuritzkes
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

3.  Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.

Authors:  Michael D Miller; Nicolas Margot; Biao Lu; Lijie Zhong; Shan-Shan Chen; Andrew Cheng; Michael Wulfsohn
Journal:  J Infect Dis       Date:  2004-02-10       Impact factor: 5.226

4.  Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.

Authors:  D R Kuritzkes; J B Quinn; S L Benoit; D L Shugarts; A Griffin; M Bakhtiari; D Poticha; J J Eron; M A Fallon; M Rubin
Journal:  AIDS       Date:  1996-08       Impact factor: 4.177

5.  Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

Authors:  Edwin DeJesus; Jürgen K Rockstroh; Keith Henry; Jean-Michel Molina; Joseph Gathe; Srinivasan Ramanathan; Xuelian Wei; Kitty Yale; Javier Szwarcberg; Kirsten White; Andrew K Cheng; Brian P Kearney
Journal:  Lancet       Date:  2012-06-30       Impact factor: 79.321

6.  Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

Authors:  David A Cooper; Roy T Steigbigel; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey L Lennox; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Hedy Teppler; Bach-Yen Nguyen
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

7.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Authors:  Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding
Journal:  JAMA       Date:  2018-07-24       Impact factor: 56.272

8.  Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors.

Authors:  E Randall Lanier; Mounir Ait-Khaled; Janna Scott; Chris Stone; Thomas Melby; Glenn Sturge; Marty St Clair; Helen Steel; Seth Hetherington; Gillian Pearce; William Spreen; Stephen Lafon
Journal:  Antivir Ther       Date:  2004-02

9.  Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Authors:  L Marije Hofstra; Nicolas Sauvageot; Jan Albert; Ivailo Alexiev; Federico Garcia; Daniel Struck; David A M C Van de Vijver; Birgitta Åsjö; Danail Beshkov; Suzie Coughlan; Diane Descamps; Algirdas Griskevicius; Osamah Hamouda; Andrzej Horban; Marjo Van Kasteren; Tatjana Kolupajeva; Leondios G Kostrikis; Kirsi Liitsola; Marek Linka; Orna Mor; Claus Nielsen; Dan Otelea; Dimitrios Paraskevis; Roger Paredes; Mario Poljak; Elisabeth Puchhammer-Stöckl; Anders Sönnerborg; Danica Staneková; Maja Stanojevic; Kristel Van Laethem; Maurizio Zazzi; Snjezana Zidovec Lepej; Charles A B Boucher; Jean-Claude Schmit; Annemarie M J Wensing; E Puchhammer-Stockl; M Sarcletti; B Schmied; M Geit; G Balluch; A-M Vandamme; J Vercauteren; I Derdelinckx; A Sasse; M Bogaert; H Ceunen; A De Roo; S De Wit; F Echahidi; K Fransen; J-C Goffard; P Goubau; E Goudeseune; J-C Yombi; P Lacor; C Liesnard; M Moutschen; D Pierard; R Rens; Y Schrooten; D Vaira; L P R Vandekerckhove; A Van den Heuvel; B Van Der Gucht; M Van Ranst; E Van Wijngaerden; B Vandercam; M Vekemans; C Verhofstede; N Clumeck; K Van Laethem; D Beshkov; I Alexiev; S Zidovec Lepej; J Begovac; L Kostrikis; I Demetriades; I Kousiappa; V Demetriou; J Hezka; M Linka; M Maly; L Machala; C Nielsen; L B Jørgensen; J Gerstoft; L Mathiesen; C Pedersen; H Nielsen; A Laursen; B Kvinesdal; K Liitsola; M Ristola; J Suni; J Sutinen; D Descamps; L Assoumou; G Castor; M Grude; P Flandre; A Storto; O Hamouda; C Kücherer; T Berg; P Braun; G Poggensee; M Däumer; J Eberle; H Heiken; R Kaiser; H Knechten; K Korn; H Müller; S Neifer; B Schmidt; H Walter; B Gunsenheimer-Bartmeyer; T Harrer; D Paraskevis; A Hatzakis; A Zavitsanou; A Vassilakis; M Lazanas; M Chini; A Lioni; V Sakka; S Kourkounti; V Paparizos; A Antoniadou; A Papadopoulos; G Poulakou; I Katsarolis; K Protopapas; G Chryssos; S Drimis; P Gargalianos; G Xylomenos; G Lourida; M Psichogiou; G L Daikos; N V Sipsas; A Kontos; M N Gamaletsou; G Koratzanis; H Sambatakou; H Mariolis; A Skoutelis; V Papastamopoulos; O Georgiou; P Panagopoulos; E Maltezos; S Coughlan; C De Gascun; C Byrne; M Duffy; C Bergin; D Reidy; G Farrell; J Lambert; E O'Connor; A Rochford; J Low; P Coakely; S O'Dea; W Hall; O Mor; I Levi; D Chemtob; Z Grossman; M Zazzi; A de Luca; C Balotta; C Riva; C Mussini; I Caramma; A Capetti; M C Colombo; C Rossi; F Prati; F Tramuto; F Vitale; M Ciccozzi; G Angarano; G Rezza; T Kolupajeva; O Vasins; A Griskevicius; V Lipnickiene; J C Schmit; D Struck; N Sauvageot; R Hemmer; V Arendt; C Michaux; T Staub; C Sequin-Devaux; A M J Wensing; C A B Boucher; D A M C van de Vijver; A van Kessel; P H M van Bentum; K Brinkman; B J Connell; M E van der Ende; I M Hoepelman; M van Kasteren; M Kuipers; N Langebeek; C Richter; R M W J Santegoets; L Schrijnders-Gudde; R Schuurman; B J M van de Ven; B Åsjö; A-M Bakken Kran; V Ormaasen; P Aavitsland; A Horban; J J Stanczak; G P Stanczak; E Firlag-Burkacka; A Wiercinska-Drapalo; E Jablonowska; E Maolepsza; M Leszczyszyn-Pynka; W Szata; R Camacho; C Palma; F Borges; T Paixão; V Duque; F Araújo; D Otelea; S Paraschiv; A M Tudor; R Cernat; C Chiriac; F Dumitrescu; L J Prisecariu; M Stanojevic; Dj Jevtovic; D Salemovic; D Stanekova; M Habekova; Z Chabadová; T Drobkova; P Bukovinova; A Shunnar; P Truska; M Poljak; M Lunar; D Babic; J Tomazic; L Vidmar; T Vovko; P Karner; F Garcia; R Paredes; S Monge; S Moreno; J Del Amo; V Asensi; J L Sirvent; C de Mendoza; R Delgado; F Gutiérrez; J Berenguer; S Garcia-Bujalance; N Stella; I de Los Santos; J R Blanco; D Dalmau; M Rivero; F Segura; M J Pérez Elías; M Alvarez; N Chueca; C Rodríguez-Martín; C Vidal; J C Palomares; I Viciana; P Viciana; J Cordoba; A Aguilera; P Domingo; M J Galindo; C Miralles; M A Del Pozo; E Ribera; J A Iribarren; L Ruiz; J de la Torre; F Vidal; B Clotet; J Albert; A Heidarian; K Aperia-Peipke; M Axelsson; M Mild; A Karlsson; A Sönnerborg; A Thalme; L Navér; G Bratt; A Karlsson; A Blaxhult; M Gisslén; B Svennerholm; I Bergbrant; P Björkman; C Säll; Å Mellgren; A Lindholm; N Kuylenstierna; R Montelius; F Azimi; B Johansson; M Carlsson; E Johansson; B Ljungberg; H Ekvall; A Strand; S Mäkitalo; S Öberg; P Holmblad; M Höfer; H Holmberg; P Josefson; U Ryding
Journal:  Clin Infect Dis       Date:  2015-11-29       Impact factor: 9.079

10.  Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapy.

Authors:  Christos Mihailidis; David Dunn; Deenan Pillay; Anton Pozniak
Journal:  AIDS       Date:  2008-01-30       Impact factor: 4.177
View more
  83 in total

1.  Association of cell free mitochondrial DNA and caspase-1 expression with disease severity and ARTs efficacy in HIV infection.

Authors:  Zain Ali; Shahid Waseem; Iram Shahzadi; Sidra Bukhari; Riffat Aysha Anis; Ibrar Ahmed; Mariam Anees
Journal:  Mol Biol Rep       Date:  2021-04-22       Impact factor: 2.316

2.  HIV-1 Genetic Diversity and Natural Polymorphisms of the Integrase Gene in Integrase Inhibitor-Naive Patients in Harare, Zimbabwe.

Authors:  Amanda Madyadi; Milcah Dhoro; Tinei Shamu; Tendai Washaya; Vinie Kouamou; Benjamin Chimukangara; David Katzenstein; Justen Manasa
Journal:  AIDS Res Hum Retroviruses       Date:  2021-12       Impact factor: 2.205

3.  An Update on Antiretroviral Therapy.

Authors:  Luis Menéndez-Arias; Samara Martín-Alonso; Estrella Frutos-Beltrán
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific.

Authors:  J Ross; A Jiamsakul; N Kumarasamy; I Azwa; T P Merati; C D Do; M P Lee; P S Ly; E Yunihastuti; K V Nguyen; R Ditangco; O T Ng; J Y Choi; S Oka; A H Sohn; M Law
Journal:  HIV Med       Date:  2020-11-05       Impact factor: 3.180

5.  Deciphering Complex Mechanisms of Resistance and Loss of Potency through Coupled Molecular Dynamics and Machine Learning.

Authors:  Florian Leidner; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  J Chem Theory Comput       Date:  2021-03-30       Impact factor: 6.006

6.  Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.

Authors:  Amy G Cutrell; Jonathan M Schapiro; Carlo F Perno; Daniel R Kuritzkes; Romina Quercia; Parul Patel; Joseph W Polli; David Dorey; Yongwei Wang; Sterling Wu; Veerle Van Eygen; Herta Crauwels; Susan L Ford; Mark Baker; Christine L Talarico; Marty St Clair; Jerry Jeffrey; C Thomas White; Simon Vanveggel; Kati Vandermeulen; David A Margolis; Michael Aboud; William R Spreen; Jan van Lunzen
Journal:  AIDS       Date:  2021-07-15       Impact factor: 4.632

7.  In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.

Authors:  Francesco Saladini; Federica Giammarino; Behnaz A Hosseini; Alessia Giannini; Adele Boccuto; Filippo Dragoni; Ilaria Vicenti; Robert W Shafer; Maurizio Zazzi
Journal:  J Antimicrob Chemother       Date:  2021-01-01       Impact factor: 5.790

8.  2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings.

Authors:  Andrew D Revell; Dechao Wang; Maria-Jesus Perez-Elias; Robin Wood; Dolphina Cogill; Hugo Tempelman; Raph L Hamers; Peter Reiss; Ard van Sighem; Catherine A Rehm; Brian Agan; Gerardo Alvarez-Uria; Julio S G Montaner; H Clifford Lane; Brendan A Larder
Journal:  J Antimicrob Chemother       Date:  2021-06-18       Impact factor: 5.790

Review 9.  HIV Protease: Historical Perspective and Current Research.

Authors:  Irene T Weber; Yuan-Fang Wang; Robert W Harrison
Journal:  Viruses       Date:  2021-05-06       Impact factor: 5.048

10.  Emergence of Human Immunodeficiency Virus-1 Drug Resistance During the 3-Month World Health Organization-Recommended Enhanced Adherence Counseling Period in the CART-1 Cohort Study.

Authors:  Jennifer A Brown; Herbert A Mbunkah; Thabo I Lejone; Isaac Ringera; Molisana Cheleboi; Thomas Klimkait; Karin J Metzner; Huldrych F Günthard; Niklaus D Labhardt; Roger D Kouyos; Nadine Tschumi
Journal:  Open Forum Infect Dis       Date:  2021-02-02       Impact factor: 3.835
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.